Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Misinterpretation of time-to-first event curves can lead to inappropriate treatment

Samy Suissa, Amnon Ariel
European Respiratory Journal 2019 54: 1901275; DOI: 10.1183/13993003.01275-2019
Samy Suissa
1Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, and the Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: samy.suissa@mcgill.ca
Amnon Ariel
2Lung Unit, Emek Medical Center, Afula, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The IMPACT trial of triple therapy in COPD confirms that benefit on exacerbations is only in first month with no benefit in following 11 months, likely due to inclusion of asthma-like patients, suggesting a precision medicine opportunity in COPD treatment http://bit.ly/2YxQpH0

From the authors:

We thank B. Hartley and co-workers for their correspondence on our analysis of the IMPACT triple therapy trial [1]. We welcome this opportunity to correct some misunderstanding of the computation of monthly rates of exacerbation, when converted from the cumulative incidence curve, as applied to the IMPACT trial.

The rate of a first exacerbation for a given month of follow-up is based not only on the gradient of the survival function as the numerator, as understood by B. Hartley and co-workers, but must also include the survival function as the denominator denoting the subjects at risk of an exacerbation [2]. Thus, the monthly rate is approximated by the difference between the cumulative incidence value at the end of each month with that at the beginning of that month, divided by the survival at the beginning of the month. Using the notation of B. Hartley and co-workers (somewhat confusing since S(t) is typically used to denote the survival function, not the cumulative incidence function as employed in their correspondence), the “rate” at a given point in time (hazard function) is:Embedded ImageThe corresponding average rate over a given time interval t1 to t2 is given by:Embedded ImageThis is the monthly rate of exacerbation displayed in our figure for the long-acting muscarinic antagonist (LAMA)–long-acting β-agonist (LABA) and triple therapy groups, approximated from the cumulative incidence curves, for the IMPACT trial [1]. It clearly shows that the first month's surge in the rate of exacerbation in the LAMA–LABA group is real, with no differences in the subsequent rates between the two groups during the following 11 months. Thus, contrary to the claim of B. Hartley and co-workers, this proper calculation of the rate supports the conclusion that the difference in the rate of exacerbation between the two groups is due to the first month's surge.

This pattern of an early surge, known as “depletion of susceptibles”, can be informative to understand a treatment's effect [3]. This sudden surge is not unexpected in the IMPACT trial with the abrupt withdrawal of inhaled corticosteroids (ICS) imposed at randomisation and its inclusion of a patient population with a history of asthma, over-represented by frequent exacerbators with milder airflow limitation [4].

Rather than this mathematical sophistication, it would have been more straightforward and certainly more informative if B. Hartley and the authors of the IMPACT trial had simply provided estimates for these monthly rates of an exacerbation directly from the trial data available to them. The authors could then confirm the surge with the actual trial data, and also investigate the role of prior ICS use that was abruptly discontinued at randomisation, as well as prior asthma diagnosis, frequent exacerbator phenotype, GOLD stage and eosinophilia, on this surge. Such analyses would provide valuable data for a better precision medicine targeting of the right treatment for the right patient [5]. Most importantly, this would also allow to prevent unnecessary harms from ICS to those patients who would not benefit from triple therapy.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01275-2019.Shareable

Footnotes

  • Conflict of interest: S. Suissa reports personal fees for board membership from Novartis and Boehringer Ingelheim, grants from Boehringer Ingelheim/Pfizer, personal fees for lectures from AstraZeneca, outside the submitted work.

  • Conflict of interest: A. Ariel reports personal fees from AstraZeneca and Teva, personal fees and non-financial support from Boehringer Ingelheim, outside the submitted work.

  • Received June 26, 2019.
  • Accepted June 27, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Suissa S,
    2. Ariel A
    . Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J 2018; 52: 1801848.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Collett D
    . Modelling Survival Data in Medical Research. London, Chapman and Hall, 1994.
  3. ↵
    1. Renoux C,
    2. Dell'Aniello S,
    3. Brenner B, et al.
    Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiol Drug Saf 2017; 26: 554–560.
    OpenUrl
  4. ↵
    1. Suissa S,
    2. Ariel A
    . Triple therapy in COPD: only for the right patient. Eur Respir J 2019; 53: 1900394.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Suissa S,
    2. Ernst P
    . Precision medicine urgency: the case of inhaled corticosteroids in COPD. Chest 2017; 152: 227–231.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 3 Table of Contents
European Respiratory Journal: 54 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Misinterpretation of time-to-first event curves can lead to inappropriate treatment
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Misinterpretation of time-to-first event curves can lead to inappropriate treatment
Samy Suissa, Amnon Ariel
European Respiratory Journal Sep 2019, 54 (3) 1901275; DOI: 10.1183/13993003.01275-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Misinterpretation of time-to-first event curves can lead to inappropriate treatment
Samy Suissa, Amnon Ariel
European Respiratory Journal Sep 2019, 54 (3) 1901275; DOI: 10.1183/13993003.01275-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Treatable traits in ILD: why not consider acute exacerbations?
  • Inclusion of lung health outcomes in TB treatment trials
  • Understanding confounding in Mendelian randomisation studies
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society